|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Restricted Stock Unit | (1) | 09/11/2020 | A | 219,000 | (2) | (2) | Common Stock | 219,000 | $ 0 | 219,000 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
White Billy Joe 535 BROADHOLLOW RD SUITE B51 MELVILLE, NY 11747 |
X |
/s/ Billy Joe White | 09/11/2020 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. |
(2) | Reporting Person was granted 219,000 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause. |